Interestingly, oral administration of 10058-F4, a c-Myc-Max interaction inhibitor, to obese mice greatly reduces obesity, IR, steatosis, and liver fibrosis. This evidence concerns the gene MYC and obesity due to melanocortin 4 receptor deficiency.